TERT
Telomerase reverse transcriptase
As of the edition of 20 October 2026, TERT (telomerase reverse transcriptase, UniProt O14746) has 2 drugs tested at it and 2 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O14746
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 32
- Disease areas
- Blood and lymph; Cancer; Immune system; Heart and blood vessels; Lungs and airways; Nervous system; Eye; Infections
- Registered trials of its drugs
- 22
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Imetelstat | Marketed | Phase 3 | none listed |
| Imetelstat sodium | Marketed | Phase 3 | Ends 2031 |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Geron | Route B |
The other 1 company at TERT
In the product2 companies in all; 1 is not named here, and no score is.
See the 2 companies at TERT, ranked, with the facts behind eachRequest access. Nothing is shown until you do.